Trian Fund Management, which owns nearly 5% of SOLVENTUM CORP, demanded the medical device maker cut overhead costs and divest non-core units. The activist firm has pressured Solventum for 18 months following its spin-off from 3M CO. Investors are weighing Trian's push for a health information systems divestiture against Solventum's existing $500 million cost-cutting plan.
Trian Calls for Cost Cuts and Divestitures at Solventum
Trian Fund Management urged Solventum to cut costs and divest its health information systems unit. The firm says the 3M spin-off needs better capital strategy.
Xurve View
Insights:
Xurve View









